Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

SCN2A mutation in an infant with Ohtahara syndrome and neuroimaging findings: expanding the phenotype of neuronal migration disorders.

Vlachou V, Larsen L, Pavlidou E, Ismayilova N, Mazarakis ND, Scala M, Pantazi M, Mankad K, Kinali M.

J Genet. 2019 Jun;98(2). pii: 54.

2.

The Interaction of Genetic Mutations in PARK2 and FA2H Causes a Novel Phenotype in a Case of Childhood-Onset Movement Disorder.

Benger M, Mankad K, Proukakis C, Mazarakis ND, Kinali M.

Front Neurol. 2019 May 29;10:555. doi: 10.3389/fneur.2019.00555. eCollection 2019.

3.

Autism spectrum disorder: prospects for treatment using gene therapy.

Benger M, Kinali M, Mazarakis ND.

Mol Autism. 2018 Jun 20;9:39. doi: 10.1186/s13229-018-0222-8. eCollection 2018. Review.

4.

Selective transduction of astrocytic and neuronal CNS subpopulations by lentiviral vectors pseudotyped with Chikungunya virus envelope.

Eleftheriadou I, Dieringer M, Poh XY, Sanchez-Garrido J, Gao Y, Sgourou A, Simmons LE, Mazarakis ND.

Biomaterials. 2017 Apr;123:1-14. doi: 10.1016/j.biomaterials.2017.01.023. Epub 2017 Jan 23.

5.

PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer's disease model.

Katsouri L, Lim YM, Blondrath K, Eleftheriadou I, Lombardero L, Birch AM, Mirzaei N, Irvine EE, Mazarakis ND, Sastre M.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12292-12297. Epub 2016 Oct 10.

6.

αCAR IGF-1 vector targeting of motor neurons ameliorates disease progression in ALS mice.

Eleftheriadou I, Manolaras I, Irvine EE, Dieringer M, Trabalza A, Mazarakis ND.

Ann Clin Transl Neurol. 2016 Sep 7;3(10):752-768. eCollection 2016 Oct.

7.

IκΒα inhibits apoptosis at the outer mitochondrial membrane independently of NF-κB retention.

Pazarentzos E, Mahul-Mellier AL, Datler C, Chaisaklert W, Hwang MS, Kroon J, Qize D, Osborne F, Al-Rubaish A, Al-Ali A, Mazarakis ND, Aboagye EO, Grimm S.

EMBO J. 2014 Dec 1;33(23):2814-28. doi: 10.15252/embj.201488183. Epub 2014 Oct 31.

8.

Anticancer gene transfer for cancer gene therapy.

Pazarentzos E, Mazarakis ND.

Adv Exp Med Biol. 2014;818:255-80. doi: 10.1007/978-1-4471-6458-6_13. Review.

PMID:
25001541
9.

Rabies virus envelope glycoprotein targets lentiviral vectors to the axonal retrograde pathway in motor neurons.

Hislop JN, Islam TA, Eleftheriadou I, Carpentier DC, Trabalza A, Parkinson M, Schiavo G, Mazarakis ND.

J Biol Chem. 2014 Jun 6;289(23):16148-63. doi: 10.1074/jbc.M114.549980. Epub 2014 Apr 21.

10.

Specific retrograde transduction of spinal motor neurons using lentiviral vectors targeted to presynaptic NMJ receptors.

Eleftheriadou I, Trabalza A, Ellison SM, Gharun K, Mazarakis ND.

Mol Ther. 2014 Jul;22(7):1285-1298. doi: 10.1038/mt.2014.49. Epub 2014 Mar 26.

11.

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA.

Lancet. 2014 Mar 29;383(9923):1138-46. doi: 10.1016/S0140-6736(13)61939-X. Epub 2014 Jan 10.

PMID:
24412048
12.

Enhanced central nervous system transduction with lentiviral vectors pseudotyped with RVG/HIV-1gp41 chimeric envelope glycoproteins.

Trabalza A, Eleftheriadou I, Sgourou A, Liao TY, Patsali P, Lee H, Mazarakis ND.

J Virol. 2014 Mar;88(5):2877-90. doi: 10.1128/JVI.03376-13. Epub 2013 Dec 26.

13.

Vesicular stomatitis virus glycoprotein- and Venezuelan equine encephalitis virus-derived glycoprotein-pseudotyped lentivirus vectors differentially transduce corneal endothelium, trabecular meshwork, and human photoreceptors.

Lipinski DM, Barnard AR, Charbel Issa P, Singh MS, De Silva SR, Trabalza A, Eleftheriadou I, Ellison SM, Mazarakis ND, MacLaren RE.

Hum Gene Ther. 2014 Jan;25(1):50-62. doi: 10.1089/hum.2013.009. Epub 2013 Dec 21.

PMID:
24125177
14.

Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum.

Ellison SM, Trabalza A, Tisato V, Pazarentzos E, Lee S, Papadaki V, Goniotaki D, Morgan S, Mirzaei N, Mazarakis ND.

Mol Ther. 2013 Oct;21(10):1862-75. doi: 10.1038/mt.2013.132. Epub 2013 Jun 25.

15.

Venezuelan equine encephalitis virus glycoprotein pseudotyping confers neurotropism to lentiviral vectors.

Trabalza A, Georgiadis C, Eleftheriadou I, Hislop JN, Ellison SM, Karavassilis ME, Mazarakis ND.

Gene Ther. 2013 Jul;20(7):723-32. doi: 10.1038/gt.2012.85. Epub 2012 Nov 22.

PMID:
23171919
16.

Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.

Kia A, Przystal JM, Nianiaris N, Mazarakis ND, Mintz PJ, Hajitou A.

Mol Cancer Ther. 2012 Dec;11(12):2566-77. doi: 10.1158/1535-7163.MCT-12-0587. Epub 2012 Oct 10.

17.

Enhanced pseudotyping efficiency of HIV-1 lentiviral vectors by a rabies/vesicular stomatitis virus chimeric envelope glycoprotein.

Carpentier DC, Vevis K, Trabalza A, Georgiadis C, Ellison SM, Asfahani RI, Mazarakis ND.

Gene Ther. 2012 Jul;19(7):761-74. doi: 10.1038/gt.2011.124. Epub 2011 Sep 8.

PMID:
21900965
18.

Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase.

Mitchell J, Paul P, Chen HJ, Morris A, Payling M, Falchi M, Habgood J, Panoutsou S, Winkler S, Tisato V, Hajitou A, Smith B, Vance C, Shaw C, Mazarakis ND, de Belleroche J.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7556-61. doi: 10.1073/pnas.0914128107. Epub 2010 Apr 5.

19.

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

Jarraya B, Boulet S, Ralph GS, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X, Hérard AS, Day DM, Brouillet E, Kingsman SM, Hantraye P, Mitrophanous KA, Mazarakis ND, Palfi S.

Sci Transl Med. 2009 Oct 14;1(2):2ra4. doi: 10.1126/scitranslmed.3000130.

20.

A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer.

Trepel M, Stoneham CA, Eleftherohorinou H, Mazarakis ND, Pasqualini R, Arap W, Hajitou A.

Mol Cancer Ther. 2009 Aug;8(8):2383-91. doi: 10.1158/1535-7163.MCT-09-0110. Epub 2009 Aug 11.

21.

Lentiviral vector expressing retinoic acid receptor beta2 promotes recovery of function after corticospinal tract injury in the adult rat spinal cord.

Yip PK, Wong LF, Pattinson D, Battaglia A, Grist J, Bradbury EJ, Maden M, McMahon SB, Mazarakis ND.

Hum Mol Genet. 2006 Nov 1;15(21):3107-18. Epub 2006 Sep 19.

PMID:
16984961
22.

Interactions between retinoic acid, nerve growth factor and sonic hedgehog signalling pathways in neurite outgrowth.

So PL, Yip PK, Bunting S, Wong LF, Mazarakis ND, Hall S, McMahon S, Maden M, Corcoran JP.

Dev Biol. 2006 Oct 1;298(1):167-75. Epub 2006 Jun 17.

23.

Reversal of neurochemical changes and pain-related behavior in a model of neuropathic pain using modified lentiviral vectors expressing GDNF.

Pezet S, Krzyzanowska A, Wong LF, Grist J, Mazarakis ND, Georgievska B, McMahon SB.

Mol Ther. 2006 Jun;13(6):1101-9. Epub 2006 Feb 28.

24.

Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.

Wong LF, Goodhead L, Prat C, Mitrophanous KA, Kingsman SM, Mazarakis ND.

Hum Gene Ther. 2006 Jan;17(1):1-9. Review. Erratum in: Hum Gene Ther. 2006 Mar;17(3):376.

PMID:
16409120
25.

Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord.

Wong LF, Yip PK, Battaglia A, Grist J, Corcoran J, Maden M, Azzouz M, Kingsman SM, Kingsman AJ, Mazarakis ND, McMahon SB.

Nat Neurosci. 2006 Feb;9(2):243-50. Epub 2005 Dec 25.

PMID:
16388307
26.

Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors.

Ralph GS, Binley K, Wong LF, Azzouz M, Mazarakis ND.

Clin Sci (Lond). 2006 Jan;110(1):37-46. Review.

PMID:
16336203
27.

Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model.

Dowd E, Monville C, Torres EM, Wong LF, Azzouz M, Mazarakis ND, Dunnett SB.

Eur J Neurosci. 2005 Nov;22(10):2587-95.

PMID:
16307601
28.

Trophic activity of Rabies G protein-pseudotyped equine infectious anemia viral vector mediated IGF-I motor neuron gene transfer in vitro.

Teng Q, Garrity-Moses M, Federici T, Tanase D, Liu JK, Mazarakis ND, Azzouz M, Walmsley LE, Carlton E, Boulis NM.

Neurobiol Dis. 2005 Dec;20(3):694-700. Epub 2005 Jul 7.

PMID:
16005636
29.

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease.

Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A.

Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56.

PMID:
15837560
30.

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.

Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, Wong LF, Bilsland LG, Greensmith L, Kingsman SM, Mitrophanous KA, Mazarakis ND, Azzouz M.

Nat Med. 2005 Apr;11(4):429-33. Epub 2005 Mar 13.

31.

Therapeutic gene silencing in neurological disorders, using interfering RNA.

Ralph GS, Mazarakis ND, Azzouz M.

J Mol Med (Berl). 2005 Jun;83(6):413-9. Epub 2005 Mar 10. Review.

PMID:
15759100
32.

Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy.

Azzouz M, Le T, Ralph GS, Walmsley L, Monani UR, Lee DC, Wilkes F, Mitrophanous KA, Kingsman SM, Burghes AH, Mazarakis ND.

J Clin Invest. 2004 Dec;114(12):1726-31.

33.

Lentiviral-mediated delivery of Bcl-2 or GDNF protects against excitotoxicity in the rat hippocampus.

Wong LF, Ralph GS, Walmsley LE, Bienemann AS, Parham S, Kingsman SM, Uney JB, Mazarakis ND.

Mol Ther. 2005 Jan;11(1):89-95.

34.

Lentiviral vectors for treating and modeling human CNS disorders.

Azzouz M, Kingsman SM, Mazarakis ND.

J Gene Med. 2004 Sep;6(9):951-62. Review.

PMID:
15352068
35.

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND.

Nature. 2004 May 27;429(6990):413-7.

PMID:
15164063
36.

Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector.

Azzouz M, Ralph S, Wong LF, Day D, Askham Z, Barber RD, Mitrophanous KA, Kingsman SM, Mazarakis ND.

Neuroreport. 2004 Apr 29;15(6):985-90.

PMID:
15076720
37.

Identification of potential stroke targets by lentiviral vector mediated overexpression of HIF-1 alpha and HIF-2 alpha in a primary neuronal model of hypoxia.

Ralph GS, Parham S, Lee SR, Beard GL, Craigon MH, Ward N, White JR, Barber RD, Rayner W, Kingsman SM, Mundy CR, Mazarakis ND, Krige D.

J Cereb Blood Flow Metab. 2004 Feb;24(2):245-58.

PMID:
14747751
38.

Transduction patterns of pseudotyped lentiviral vectors in the nervous system.

Wong LF, Azzouz M, Walmsley LE, Askham Z, Wilkes FJ, Mitrophanous KA, Kingsman SM, Mazarakis ND.

Mol Ther. 2004 Jan;9(1):101-11. Erratum in: Mol Ther. 2004 May;9(5):765.

39.

Long-term replacement of a mutated nonfunctional CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin.

Bienemann AS, Martin-Rendon E, Cosgrave AS, Glover CP, Wong LF, Kingsman SM, Mitrophanous KA, Mazarakis ND, Uney JB.

Mol Ther. 2003 May;7(5 Pt 1):588-96.

41.

Retinoic acid receptor beta2 and neurite outgrowth in the adult mouse spinal cord in vitro.

Corcoran J, So PL, Barber RD, Vincent KJ, Mazarakis ND, Mitrophanous KA, Kingsman SM, Maden M.

J Cell Sci. 2002 Oct 1;115(Pt 19):3779-86.

42.

New methods to titrate EIAV-based lentiviral vectors.

Martin-Rendon E, White LJ, Olsen A, Mitrophanous KA, Mazarakis ND.

Mol Ther. 2002 May;5(5 Pt 1):566-70.

43.

Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors.

Rohll JB, Mitrophanous KA, Martin-Rendon E, Ellard FM, Radcliffe PA, Mazarakis ND, Kingsman SM.

Methods Enzymol. 2002;346:466-500. No abstract available.

PMID:
11883086
44.

Lentiviral vectors for the treatment of neurodegenerative diseases.

Martin-Rendon E, Azzouz M, Mazarakis ND.

Curr Opin Mol Ther. 2001 Oct;3(5):476-81. Review.

PMID:
11699892
45.

Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.

Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, Carter EE, Barber RD, Baban DF, Kingsman SM, Kingsman AJ, O'Malley K, Mitrophanous KA.

Hum Mol Genet. 2001 Sep 15;10(19):2109-21.

PMID:
11590128
46.

Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: implications for neurological impairment associated with maple syrup urine disease.

Jouvet P, Rustin P, Taylor DL, Pocock JM, Felderhoff-Mueser U, Mazarakis ND, Sarraf C, Joashi U, Kozma M, Greenwood K, Edwards AD, Mehmet H.

Mol Biol Cell. 2000 May;11(5):1919-32.

47.

Maple syrup urine disease metabolites induce apoptosis in neural cells without cytochrome c release or changes in mitochondrial membrane potential.

Jouvet P, Rustin P, Felderhoff U, Pocock J, Joashi U, Mazarakis ND, Sarraf C, Edwards AD, Mehmet H.

Biochem Soc Trans. 1998 Nov;26(4):S341. No abstract available.

PMID:
10047855
48.

Poly(ADP ribose) polymerase cleavage precedes neuronal death in the hippocampus and cerebellum following injury to the developing rat forebrain.

Joashi UC, Greenwood K, Taylor DL, Kozma M, Mazarakis ND, Edwards AD, Mehmet H.

Eur J Neurosci. 1999 Jan;11(1):91-100.

PMID:
9987014
49.

Apoptosis in neural development and disease.

Mazarakis ND, Edwards AD, Mehmet H.

Arch Dis Child Fetal Neonatal Ed. 1997 Nov;77(3):F165-70. Review. No abstract available.

50.

Differential induction of apoptosis in Swiss 3T3 cells by nitric oxide and the nitrosonium cation.

Khan S, Kayahara M, Joashi U, Mazarakis ND, Sarraf C, Edwards AD, Hughes MN, Mehmet H.

J Cell Sci. 1997 Sep;110 ( Pt 18):2315-22.

Supplemental Content

Loading ...
Support Center